1e
19
1
49
2
2
18
1b
1d
18
3a
4d
1d
2 29
1d
25
Sydney M. Evans V.M.D., M.S.
78
4d
Emeritus Professor of Radiation Oncology
28
99
3
69
Education Officer, University of Pennsylvania School of Medicine Department of Radiation Oncology
a4
Vice Chair, Faculty Affairs, University of Pennsylvania, School of Medicine, Department of Radiation Oncology
11
Department: Radiation Oncology
4
1
b
1d
46
Contact information
46
4
3
3
3
2
29
4
b
1f
46
187 John Morgan Building
35 3620 Hamilton Walk
Philadelphia, PA 19104
26
35 3620 Hamilton Walk
Philadelphia, PA 19104
2e
Office: 215-898-0074
30
9f
12
30
13
Education:
21 7 BS 24 (Pre-Veterinary Medicine) c
3c Rutgers University, Douglas College, 1973.
21 8 VMD 20 (Veterinary Medicine) c
54 University of Pennsylvania, School of Veterinary Medicine , 1977.
21 7 MS 29 (Comparative Medical Sciences) c
53 University of Pennsylvania, School of Veterinary Medicine , 1986.
c
3
3
3
3
8b
Permanent link21 7 BS 24 (Pre-Veterinary Medicine) c
3c Rutgers University, Douglas College, 1973.
21 8 VMD 20 (Veterinary Medicine) c
54 University of Pennsylvania, School of Veterinary Medicine , 1977.
21 7 MS 29 (Comparative Medical Sciences) c
53 University of Pennsylvania, School of Veterinary Medicine , 1986.
c
2 29
21
1e
1d
24
5e
89 Measuring hypoxia in vivo; Animal Models of human disease; Cancer physiology, proliferation; Cancer physiology; tumor vasculature
8
1b RESEARCH INTERESTS:
688 The primary emphasis of the work in the Evans laboratory is to determine causes of treatment resistance in human cancer. The treatment resistance factor that is emphasized is hypoxia. The presence, level and distribution of hypoxia is measured using a 2-nitroimidazole agent, EF5, developed by Dr. Cameron Koch, also from the Department of Radiation Oncology, at PENN. EF5 can be used for in vitro or in vivo studies. The majority of studies in the Evans laboratory involve in vivo studies in animals or humans. Given intravenously, this agent is reduced and bound in hypoxic cells. The adducts thus formed are recognized by a specific fluorescent monoclonal antibody. Tumor tissue or cells are studied either using immunohistochemistry or flow cytometry. This fluorescence can be measured and converted into tissue pO2 based upon previously published in vitro studies. We have performed studies using EF5 in animal models of cancer and, since 1998 have been performing clinical trials to evaluate the presence and level of hypoxia in various human cancers. We are currently funded by the NIH to perform studies in human brain tumors, head and neck cancers, sarcomas, cervix, and intraperitoneal cancers. We have shown that hypoxia, as measured by EF5 binding correlates to the level of tumor aggression in glial brain tumors, soft tissue sarcomas and head/neck squamous cell cancers. We have recently been able to produce [F-18]-EF5, which can be analyzed with positron emission tomography, PET imaging. Grants to study EF5 binding, with both immunohistochemical and PET endpoints in patients with brain tumors and head and neck cancer have been funded by the NIH.
65
4b Measuring hypoxia and predicting treatment responsein cervix cancer
63 Measuring hypoxia and predicting treatment responsein head and neck squamous cell carcinoma
5d Measuring hypoxia and predicting treatment responsein carcinomatosis and sarcomatosis
4d Measuring hypoxia and predicting treatment responsein pleural cancers
52 Measuring hypoxia and predicting treatment response in soft tissue sarcomas
62
16 Mentoring women
e 29
27
Description of Research Expertise
1b KEYWORDS:89 Measuring hypoxia in vivo; Animal Models of human disease; Cancer physiology, proliferation; Cancer physiology; tumor vasculature
8
1b RESEARCH INTERESTS:
688 The primary emphasis of the work in the Evans laboratory is to determine causes of treatment resistance in human cancer. The treatment resistance factor that is emphasized is hypoxia. The presence, level and distribution of hypoxia is measured using a 2-nitroimidazole agent, EF5, developed by Dr. Cameron Koch, also from the Department of Radiation Oncology, at PENN. EF5 can be used for in vitro or in vivo studies. The majority of studies in the Evans laboratory involve in vivo studies in animals or humans. Given intravenously, this agent is reduced and bound in hypoxic cells. The adducts thus formed are recognized by a specific fluorescent monoclonal antibody. Tumor tissue or cells are studied either using immunohistochemistry or flow cytometry. This fluorescence can be measured and converted into tissue pO2 based upon previously published in vitro studies. We have performed studies using EF5 in animal models of cancer and, since 1998 have been performing clinical trials to evaluate the presence and level of hypoxia in various human cancers. We are currently funded by the NIH to perform studies in human brain tumors, head and neck cancers, sarcomas, cervix, and intraperitoneal cancers. We have shown that hypoxia, as measured by EF5 binding correlates to the level of tumor aggression in glial brain tumors, soft tissue sarcomas and head/neck squamous cell cancers. We have recently been able to produce [F-18]-EF5, which can be analyzed with positron emission tomography, PET imaging. Grants to study EF5 binding, with both immunohistochemical and PET endpoints in patients with brain tumors and head and neck cancer have been funded by the NIH.
65
Description of Clinical Expertise
54 Measuring hypoxia and predicting treatment response in brain tumors4b Measuring hypoxia and predicting treatment responsein cervix cancer
63 Measuring hypoxia and predicting treatment responsein head and neck squamous cell carcinoma
5d Measuring hypoxia and predicting treatment responsein carcinomatosis and sarcomatosis
4d Measuring hypoxia and predicting treatment responsein pleural cancers
52 Measuring hypoxia and predicting treatment response in soft tissue sarcomas
62
Description of Other Expertise
2a Mentoring junior faculty16 Mentoring women
e 29
23
159 Lao Z, Kelly CJ, Yang XY, Jenkins WT, Toorens E, Ganguly T, Evans SM, Koch CJ.: Improved Methods to Generate Spheroid Cultures from Tumor Cells, Tumor Cells & Fibroblasts or Tumor-Fragments: Microenvironment, Microvesicles and miRNA. PLoS One 10(7): e0133895, Jul 24 2015
226 Morgans AK, van Bommel AC, Stowell C, Abrahm JL, Basch E, Bekelman JE, Berry DL, Bossi A, Davis ID, de Reijke TM, Denis LJ, Evans SM, Fleshner NE, George DJ, Kiefert J, Lin DW, Matthew AG, McDermott R, Payne H, Roos IA, Schrag D, Steuber T, Tombal B, van Basten JP, van der Hoeven JJ, Penson DF: Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. European Urology 68(5): 891-8, Nov 2015.
d6 Koch CJ, Evans SM: Pharmacokinetic and pharmacodynamic modifiers of EF5 uptake and binding. Journal of Nuclear Medicine 56(4): 653, Apr 2015.
c8 Koch CJ, Evans SM: Optimizing Hypoxia Detection and Treatment Strategies. Seminars in Nuclear Medicine 45(2): 163-76, Mar 2015.
15c Koch CJ, Lustig RA, Yang XY, Jenkins WT, Wolf RL, Martinez-Lage M, Desai A, Williams D, Evans SM: Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients. Translational Oncology 7(6): 752-8, Dec 2014.
139 Koch CJ, Jenkins WT, Jenkins KW, Yang XY, Shuman AL, Pickup S, Riehl1 CR, Paudya R, Poptani H, Evans SM: Mechanisms of Blood Flow and Hypoxia Production in Rat 9L Epigastric Tumors. Tumor Microenvironment and Therapy 1(1): 1-13, Jan 2013.
142 Sood N, Jenkins WT, Yang XY, Shah NN, Katz JS, Koch CJ, Frail PR, Therien MJ, Hammer DA, Evans SM.: Biodegradable polymersomes for the delivery of Gemcitabine to Panc-1 cells. Journal of Pharmaceutics. Hindawi Publishing Company, 2013: 932797, 2013.
3c Lilie L Lin, LL 13 Antti Silvoniemi 10 James B Stubbs f Ramesh Rengan 10 Sami Suilamo c Olof Solin 12 Chaitanya Divgi e Olli Eskola 15 Jonathan M. Sorger 14 Michael G. Stabin 12 Alexander Kachur 11 Stephen M. Hahn 11 Tove Grönroos 12 Sarita Forsback 11 Sydney M Evans 11 Cameron J. Koch c9 Heikki Minn: Radiation Dosimetry and Biodistribution of the Hypoxia Tracer 18F-EF5 in Oncologic Patients. Cancer Biotherapy & Radiopharmaceuticals 27(7): 412-9, Sep 2012.
152 Marotta D, Karar J, Jenkins WT, Kumanova M, Tobias JW, Baldwin D, Hadjigeorgiou A, Alexiou P, Evans SM, Alarcon R, Maity A, Koch CJ, Koumenis C: In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection. Cancer Research 36 (eds.). 71(3): 779-89, Feb 2011
2c
7
1d
1f
Selected Publications
168 Evans SM, Putt M, Yang XY, Lustig RA, Martinez-Lage M, Williams D, Desai A, Wolf R, Brem S, Koch CJ.: Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. Journal of Neuro-Oncology 127(2): 391-400, Apr 2016.159 Lao Z, Kelly CJ, Yang XY, Jenkins WT, Toorens E, Ganguly T, Evans SM, Koch CJ.: Improved Methods to Generate Spheroid Cultures from Tumor Cells, Tumor Cells & Fibroblasts or Tumor-Fragments: Microenvironment, Microvesicles and miRNA. PLoS One 10(7): e0133895, Jul 24 2015
226 Morgans AK, van Bommel AC, Stowell C, Abrahm JL, Basch E, Bekelman JE, Berry DL, Bossi A, Davis ID, de Reijke TM, Denis LJ, Evans SM, Fleshner NE, George DJ, Kiefert J, Lin DW, Matthew AG, McDermott R, Payne H, Roos IA, Schrag D, Steuber T, Tombal B, van Basten JP, van der Hoeven JJ, Penson DF: Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. European Urology 68(5): 891-8, Nov 2015.
d6 Koch CJ, Evans SM: Pharmacokinetic and pharmacodynamic modifiers of EF5 uptake and binding. Journal of Nuclear Medicine 56(4): 653, Apr 2015.
c8 Koch CJ, Evans SM: Optimizing Hypoxia Detection and Treatment Strategies. Seminars in Nuclear Medicine 45(2): 163-76, Mar 2015.
15c Koch CJ, Lustig RA, Yang XY, Jenkins WT, Wolf RL, Martinez-Lage M, Desai A, Williams D, Evans SM: Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients. Translational Oncology 7(6): 752-8, Dec 2014.
139 Koch CJ, Jenkins WT, Jenkins KW, Yang XY, Shuman AL, Pickup S, Riehl1 CR, Paudya R, Poptani H, Evans SM: Mechanisms of Blood Flow and Hypoxia Production in Rat 9L Epigastric Tumors. Tumor Microenvironment and Therapy 1(1): 1-13, Jan 2013.
142 Sood N, Jenkins WT, Yang XY, Shah NN, Katz JS, Koch CJ, Frail PR, Therien MJ, Hammer DA, Evans SM.: Biodegradable polymersomes for the delivery of Gemcitabine to Panc-1 cells. Journal of Pharmaceutics. Hindawi Publishing Company, 2013: 932797, 2013.
3c Lilie L Lin, LL 13 Antti Silvoniemi 10 James B Stubbs f Ramesh Rengan 10 Sami Suilamo c Olof Solin 12 Chaitanya Divgi e Olli Eskola 15 Jonathan M. Sorger 14 Michael G. Stabin 12 Alexander Kachur 11 Stephen M. Hahn 11 Tove Grönroos 12 Sarita Forsback 11 Sydney M Evans 11 Cameron J. Koch c9 Heikki Minn: Radiation Dosimetry and Biodistribution of the Hypoxia Tracer 18F-EF5 in Oncologic Patients. Cancer Biotherapy & Radiopharmaceuticals 27(7): 412-9, Sep 2012.
152 Marotta D, Karar J, Jenkins WT, Kumanova M, Tobias JW, Baldwin D, Hadjigeorgiou A, Alexiou P, Evans SM, Alarcon R, Maity A, Koch CJ, Koumenis C: In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection. Cancer Research 36 (eds.). 71(3): 779-89, Feb 2011
2c